Abstracts tagged "Biologic drugs"

Abstract Number: 2650 • 2016 ACR/ARHP Annual Meeting
Prediction of Inhibition of Radiographic Progression By Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, in Patients with Active Rheumatoid Arthritis Despite Disease-Modifying Anti-Rheumatic Drug Treatment: Results of a Global, Phase 3 Trial
George Karpouzas¹, Tsutomu Takeuchi², Carter Thorne³, Shihong Sheng⁴, Xiaoming Li⁴, Ravi Rao⁵, Kaiyin Fei⁴ and Benjamin Hsu⁴, ¹Division of Rheumatology, Harbor-UCLA Medical Center, Torrance, CA, ²Division of Rheumatology, Keio University School of Medicine, Tokyo, Japan, ³University of Toronto and Southlake Regional Health Centre, Toronto, ON, Canada, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵GSK Medicines Research Centre, Stevenage, Hertfordshire, United Kingdom
Background/Purpose: In the SIRROUND-D study, sirukumab, a human anti–IL-6 cytokine monoclonal antibody, significantly reduced radiographic progression after 52 wks of treatment vs placebo in patients…
Abstract Number: 951 • 2016 ACR/ARHP Annual Meeting
A Nationwide Non-Medical Switch from Originator to Biosimilar Infliximab in Patients with Inflammatory Arthritis. Eleven Months’ Clinical Outcomes from the Danbio Registry
Bente Glintborg¹, Inge Juul Sørensen², Dorte Vendelbo Jensen², Niels Steen Krogh³, Anne Gitte Loft⁴, Jakob Espesen², Jimmi Olsen², Oliver Hendricks⁵, Jolanta Grydehøj², Inger Marie Jensen Hansen², Michael Veedfald Sørensen², Stavros Chrysidis², Birgitte Lange Andersen², Natalia Manilo², Mette Klarlund², Lis Smedegaard Andersen², Henrik Nordin², Salome Kristensen², Jesper Nørregaard² and Merete Lund Hetland¹, ¹Danish Rheumatologic Biobank and DANBIO registry, Rigshospitalet, Glostrup, Gentofte and Herlev University Hospital, Copenhagen, Denmark, ²The DANBIO registry and the Danish Departments of Rheumatology, Copenhagen, Denmark, ³ZiteLab ApS, Copenhagen, Denmark, ⁴Departments of Rheumatology at Vejle and Aarhus Hospitals, Vejle and Aarhus, Denmark, ⁵Dep. of Rheumatology, King Christians Hospital for Rheumatic Diseases, Copenhagen, Denmark
Background/Purpose: According to national guidelines issued in May 2015, a non-medical switch from originator infliximab (IFX) (Remicade) to biosimilar Remsima was conducted in all Danish…
Abstract Number: 2655 • 2016 ACR/ARHP Annual Meeting
Prevalence and Risk Factors of Reactivation of Resolved Hepatitis B Virus in Rheumatoid Arthritis Patients Treated with Biological Disease-Modifying Anti-Rheumatic Drugs
Toshiyuki Watanabe¹, Shinji Fukaya² and Kazumasa Akikawa², ¹3rd Department of Internal Medicine, Hokkaido P.W.F.A.C Obihiro-Kosei General Hospital, Obihiro, Japan, ²3rd Department of Internal medicine, Hokkaido P.W.F.A.C Obihiro-Kosei General Hospital, Obihiro, Japan
Background/Purpose: Reactivation of hepatitis B virus (HBV) is one of the most serious complications in rheumatoid arthritis (RA) patients treated with biological disease-modifying anti-rheumatic drugs…
Abstract Number: 1004 • 2016 ACR/ARHP Annual Meeting
Herpes Zoster Virus Infection in Patients Treated with Biological Therapies (BIOBADASAR)
Juan Pablo Pirola¹, Soledad Retamozo², Diego Baenas³, Alejandro Alvarellos⁴, Francisco Caeiro⁵, María Celina De La Vega⁶, Gustavo Casado⁷, Gimena Gomez⁸, Javier Roberti⁶, Osvaldo Luis Cerda⁹, Maria de los Angeles Gallardo¹⁰, Ana Quinteros¹¹, Ida Exeni¹², Juan Manuel Bande¹³, Pablo Astesana¹⁴, Analia Alvarez¹⁵, Amelia Granel¹⁶, Alejandra Peluzzon¹⁷, Ana Capuccio¹⁸, Romina Nieto¹⁹, Rossana Quintana²⁰, Eduardo Mussano²¹, Santiago Scarafia²², Carolina Costi²³, Mercedes De La Sota²⁴, Monica Patricia Diaz²⁵, Edson Javier Velozo²⁶, Santiago Aguero²⁷, Cristina Battagliotti²⁸, Sidney Soares de Souza²⁹, Emilia Cavillon³⁰, Analia Bohr³¹, Andrea Smichowski³², Alejandro Benitez³³, Daniela Vidal³⁴, Dora Pereira³⁵, Liliana Martinez³⁶, Luis Somma³⁷, Marta Zalazar³⁸, Pablo Finucci Curi³⁹, Leandro Carlevaris⁴⁰, Guillermo Berbotto⁴¹ and Veronica Saurit¹, ¹Rheumatology, Hospital Privado Centro Médico de Córdoba, Córdoba, Argentina, ²Rheumatology Unit, Hospital Privado Centro Médico de Córdoba, Argentina, Córdoba, Argentina, ³Hospital Privado Centro Médico de Córdoba, Córdoba, Argentina, ⁴Rheumatology, Hospital Privado Centro Médico de Córdoba, Cordoba, Argentina, ⁵Reumatología, Hospital Privado Centro Médico de Córdoba, Córdoba, Argentina, ⁶SAR, CABA, Argentina, ⁷Sociedad Argentina de Reumatologia, CABA, Argentina, ⁸Section of Rheumatology an, SAR, CABA, Argentina, ⁹IREP, CABA, Argentina, ¹⁰Hospital Italiano de Buenos Aires, CABA, Argentina, ¹¹Centro Integral Reumatológico, Tucuman, Argentina, ¹²Sanatorio Parque, Córdoba, Argentina, ¹³Hospital Tornú, CABA, Argentina, ¹⁴Sanatorio Allende, Cordoba, Argentina, ¹⁵Hospital Penna, Bahía Blanca, Argentina, ¹⁶Centro Platense de Reumatología, La Plata, Argentina, ¹⁷Hospital Clínica José de San Martín, CABA, Argentina, ¹⁸Hospital Cesar Milstein, CABA, Argentina, ¹⁹Hospital Provincial, Rosario, Argentina, ²⁰Sanatorio Parque, Rosario, Argentina, ²¹Córdoba, Hospital Nacional de Clínicas, Córdoba, Argentina, ²²Hospital Bernardino Rivadavia, CABA, Argentina, ²³Hospital San Martín, LaPlata, Argentina, ²⁴Consultorios, Bahia Blanca, Argentina, ²⁵Hospital Zonal Bariloche, Bariloche, Argentina, ²⁶Rheumatology, Sanatorio Adventista del Plata, Entre Rios, Argentina, ²⁷Sanatorio Pasteur, Catamarca, Argentina, ²⁸Hospital de Niños Dr Orlando Alasia, Santa Fé, Argentina, ²⁹Ramallo 1851, REUMAR, CABA, Argentina, ³⁰Consultorio, Cordoba, Argentina, ³¹Hospital de Rehabilitación Rocca, CABA, Argentina, ³²Atención Integral de Reumatología, CABA, Argentina, ³³CEIM, CABA, Argentina, ³⁴Hospital de Niños de Córdoba, Córdoba, Argentina, ³⁵Centro Raquis, Buenos Aires, Argentina, ³⁶Hospital Fernandez, CABA, Argentina, ³⁷SOMMA, Buenos Aires, Argentina, ³⁸Hospital Pirovano, CABA, Argentina, ³⁹Centro Médico Mitre, Entre Rios, Argentina, ⁴⁰IARI, CABA, Argentina, ⁴¹Sanatorio Británico, Rosario, Argentina
Background/Purpose: Biologic therapies (bDMARDs) have improved the treatment of rheumatic diseases; however, the risk of herpes zoster (HZ) virus infection or reactivation in patients treated…
Abstract Number: 3013 • 2016 ACR/ARHP Annual Meeting
Dose Reduction or Discontinuation of Biological Therapy in Patients with Rheumatoid Arthritis in Remission – 1-Year Results of a Guideline-Directed Longitudinal Cohort Study
Cecilie Heegaard Brahe¹, Simon Krabbe², Mikkel Østergaard³, Henrik Rogind⁴, Hanne Slott Jensen³, Annette Hansen⁵, Jesper Nørregaard⁶, Søren Jacobsen⁷, Lene Terslev⁸, Tuan K. Huynh⁹, Dorte Vendelbo Jensen⁵, Natalia Manilo¹⁰, Karsten Heller Asmussen¹¹, Per Brown-Frandsen⁷, Mikael Boesen¹², Zoreh Rastiemadabadi¹³, Daniel Glinatsi¹⁴, Lone Morsel-Carlsen¹⁵, Jakob M. Møller¹⁶, Niels Steen Krogh¹⁷ and Merete Lund Hetland^3,18, ¹Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Denmark, Glostrup, Denmark, ²Center for Rheumatology and Spine diseases, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Denmark, Glostrup, Denmark, ³Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Denmark, Copenhagen, Denmark, ⁴Center for Rheumatology and Spine Diseases, Center for Rheumatology and Spine Diseases, Rigshospitalet - Glostrup, University of Copenhagen, Denmark, Glostrup, Denmark, ⁵DANBIO, On behalf of Depts of Rheumatology, North, South, Central, Zealand and Capital Region, Copenhagen, Denmark, ⁶Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, ⁷Center for Rheumatology and Spine Diseases, Rigshospitalet - Glostrup, University of Copenhagen, Denmark, Glostrup, Denmark, ⁸Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Copenhagen Center for Arthritis Research (COPECARE), Copenhagen, Denmark, ⁹Department of Rheumatology, Copenhagen University Hospital at Nordsjælland, Denmark, Hillerød, Denmark, ¹⁰The DANBIO registry and the Danish Departments of Rheumatology, Copenhagen, Denmark, ¹¹Department of Rheumatology, Copenhagen University Hospital at Frederiksberg-Bispebjerg, Denmark, Frederiksberg, Denmark, ¹²Frederiksberg Hospital, Parker Institute, Frederiksberg, Denmark, ¹³Department of Radiology, Frederiksberg Hospital, Frederiksberg, Denmark, ¹⁴Center for Rheumatology and Spine Diseases, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, Glostrup, Denmark, ¹⁵Department of Radiology, Rigshospitalet, Copenhagen, Denmark, ¹⁶Department of Radiology, Copenhagen University Hospital Herlev and Gentofte, Herlev, Denmark, ¹⁷Zitelab, Frederiksberg, Denmark, ¹⁸Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, The Danish Rheumatologic Database (DANBIO), Glostrup Hospital., Copenhagen, Denmark
Background/Purpose: Dose tapering in patients in remission has previously proven promising in randomized controlled trials. However, systematic implementation in clinical practice is lacking. A new…
Abstract Number: 1045 • 2016 ACR/ARHP Annual Meeting
2016 Update of the ASAS-EULAR Management Recommendations for Axial Spondyloarthritis
Désirée van der Heijde¹, Sofia Ramiro², Robert Landewé³, Xenofon Baraliakos⁴, Filip van Den Bosch⁵, Alexandre Sepriano², Andrea Regel⁶, John D. Reveille⁷ and Jürgen Braun⁶, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Leiden University Medical Center, Leiden, Netherlands, ³Clinical Immunology and Rheumatology, Amsterdam Rheumatology Center, Amsterdam, Netherlands, ⁴Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ⁵Rheumatology, Ghent University Hospital, Ghent, Belgium, ⁶Rheumazentrum Ruhrgebiet, Herne, Germany, ⁷Rheumatology, University of Texas-McGovern Medical School, Houston, TX
Background/Purpose: In 2010 the latest ASAS-EULAR recommendations for AS and the ASAS recommendations for the use of TNF-inhibitors (TNFi) have been published. Since then new…
Abstract Number: 3219 • 2016 ACR/ARHP Annual Meeting
Altered microRNA Expression Pattern in Synovial and Blood Neutrophils in Rheumatoid Arthritis Reveals the Pathogenic Profile of These Cells. Effect of Biological Therapies
Nuria Barbarroja¹, Ivan Arias de la Rosa¹, Carlos Perez-Sanchez¹, Yolanda Jiménez-Gómez¹, Maria Carmen Abalos-Aguilera², Miguel Angel Caracuel-Ruiz³, Jerusalem Calvo-Gutierrez¹, Rafaela Ortega-Castro¹, Eduardo Collantes-Estévez¹, Alejandro Escudero-Contreras¹, Chary Lopez-Pedrera¹ and Patricia Ruiz-Limon², ¹Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ²Rheumatology Service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ³Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain
Background/Purpose: MicroRNAs (miRNA) have recently emerged as a new class of modulators of gene expression, regulating inflammation, degradation of extracellular matrix and invasive behavior of the…
Abstract Number: 1207 • 2016 ACR/ARHP Annual Meeting
Design of a Multiplex Serum Proteome Assay to Monitor Biologic Drug Response in Rheumatoid Arthritis Patients
Niamh Callan¹, Aisha Butt¹, Stephen R. Pennington², Cathy McGeough³, Philip Gardiner⁴, Gary Wright⁵, Tony Bjourson³ and David S. Gibson⁶, ¹Proteome Research Centre, Conway Institute, University College Dublin, Dublin, Ireland, ²Proteome Research Centre, Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland, ³Northern Ireland Centre for Stratified Medicine, Ulster University, Londonderry, United Kingdom, ⁴Rheumatology, Altnagelvin Hospital, Londonderry, United Kingdom, ⁵Rheumatology, Musgrave Park Hospital, BELFAST, United Kingdom, ⁶Inflammatory Disease Research Group, Northern ireland Centre for Stratified Medicine, Ulster University, Londonderry, United Kingdom
Background/Purpose: Biologic drugs have revolutionised the treatment of Rheumatoid Arthritis (RA), however these therapies are expensive and exhibit a high non–response rate (30%). Currently there…
Abstract Number: 3222 • 2016 ACR/ARHP Annual Meeting
Efficacy and Safety of Monotherapy with Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, Compared with Adalimumab Monotherapy in Biologic-Naive Patients with Active Rheumatoid Arthritis: Results of a Global, Randomized, Double-Blind, Parallel-Group, Phase 3 Study
Peter C. Taylor¹, Michael Schiff², Qingmin Wang³, Yusang Jiang³, Regina Kurrasch⁴, Shruti Daga⁵, Ravi Rao⁶, Benjamin Hsu³ and Paul-Peter Tak⁷, ¹Kennedy Institute of Rheumatology, NDORMs, University of Oxford, Oxford, United Kingdom, ²University of Colorado, School of Medicine, Denver, CO, ³Janssen Research & Development, LLC, Spring House, PA, ⁴GlaxoSmithKline, Collegeville, PA, ⁵GlaxoSmithKline, Uxbridge, United Kingdom, ⁶GSK Medicines Research Centre, Stevenage, Hertfordshire, United Kingdom, ⁷GlaxoSmithKline, Stevenage, Hertfordshire, United Kingdom
Background/Purpose: Sirukumab, a human monoclonal antibody that selectively binds to the cytokine IL-6 with high affinity, is under development for rheumatoid arthritis (RA) and other…
Abstract Number: 1518 • 2016 ACR/ARHP Annual Meeting
Immunoglobulin Binding Protein (BiP), an Antigen for CCP Sero-Positive Rheumatoid Arthritis Patients, Can Result in a False Positive Quantiferon-Gold Tuberculosis Test
JoAnn Ball¹, Kelsy Greenwald¹, Atul A. Deodhar² and Kevin L. Winthrop³, ¹Rheumatology, Desert Medical Advances, Palm Desert, CA, ²Division of Arthritis & Rheumatic Diseases OP09, Oregon Health & Science University, Portland, OR, ³Oregon Health and Sciences University, Portland, OR
Background/Purpose: Citrullinated BiP is a newly described target for cyclic citrullinated peptide(CCP). BiP in both serum and synovial fluid is over-expressed in RA patients and…
Abstract Number: 3223 • 2016 ACR/ARHP Annual Meeting
Efficacy and Safety of Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, in Patients with Active Rheumatoid Arthritis Despite Anti-TNF Therapy: Results from a Randomized, Double-Blind, Placebo-Controlled, Global, Phase 3 Study
Daniel Aletaha¹, Clifton Bingham III², Yoshiya Tanaka³, Prasheen Agarwal⁴, Regina Kurrasch⁵, Paul-Peter Tak⁶ and Sharon Popik⁴, ¹Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ²Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³University of Occupational and Environmental Health, Kitakyushu, Japan, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵GlaxoSmithKline, Collegeville, PA, ⁶GlaxoSmithKline, Stevenage, Hertfordshire, United Kingdom
Background/Purpose: Sirukumab is a human monoclonal antibody that selectively binds to the IL-6 cytokine with high affinity and is under development for rheumatoid arthritis (RA)…
Abstract Number: 1679 • 2016 ACR/ARHP Annual Meeting
Predictors of Persistency with TNFi in Biologic-Experienced Versus Biologic-Naive Psa Patients Enrolled in the Corrona Registry
CJ Etzel¹, Bradley S. Stolshek², Sabrina Rebello³, David Collier⁴, Alex Mutebi⁵, Sally W Wade⁶, Wendi Malley⁷, JD Greenberg⁷ and Leslie R Harrold⁸, ¹The University of Texas MD Anderson Cancer Center, Houston, TX, ²Amgen, Thousand Oaks, CA, ³Epidemiology, Corrona, LLC, Southborough, MA, ⁴Amgen Inc., Thousand Oaks, CA, ⁵Global Health Economics, Amgen, Thousand Oaks, CA, ⁶Wade Outcomes Research and Consulting, Salt Lake City, UT, ⁷Corrona, LLC, Southborough, MA, ⁸UMass Medical School, Worcester, MA
Background/Purpose: Little is known about factors associated with persistency of TNFi use among biologic-naïve and biologic-experienced Psoriatic Arthritis (PsA) patients in routine clinical practice in…
Abstract Number: 97 • 2016 ACR/ARHP Annual Meeting
Effects of DMARD Tapering on Treatment Costs and Work Productivity in Rheumatoid Arthritis Patients- an Analysis from the Prospective Randomized Controlled Retro- Study
Melanie Hagen¹, Camille P Figueiredo², Jayme Fogagnolo Cobra³, Judith Haschka⁴, Michaela Reiser⁵, Matthias Englbrecht⁶, Axel J. Hueber⁷, Bernhard Manger⁶, Arnd Kleyer⁸, Stephanie Finzel⁹, Hans-Peter Tony¹⁰, Stefan Kleinert¹¹, Joerg Wendler¹², Florian Schuch¹², Monika Ronneberger¹², Martin Feuchtenberger¹³, Martin Fleck¹⁴, Karin Manger¹⁵, Wolfgang Ochs¹⁶, Matthias Schmitt-Haendle¹⁷, H.-M. Lorenz¹⁸, HG Nüßlein¹⁹, R Alten²⁰, Joerg C. Henes²¹, Klaus Krüger²², Georg Schett⁷ and Juergen Rech⁷, ¹Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nuremberg (FAU), Erlangen, Germany, ²Rheumatology Division, Faculdade de Medicina da USP, São Paulo, Brazil, ³Instituto de Reumatologia de Sao Paolo, Sao Paolo, Brazil, ⁴Medical Department II, St. Vincent Hospital, the VINFORCE Study Group, Academic Teaching Hospital of Medical University of Vienna, Vienna, Austria, Vienna, Austria, ⁵Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany, ⁶Department of Internal Medicine 3, Rheumatology & Clinical Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany, ⁷Department of Internal Medicine 3 – Rheumatology and Immunology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany, ⁸Department of Internal Medicine 3, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany, ⁹Rheumatology and Clinical Immunology, University Medical Center Freiburg, Freiburg, Freiburg, Germany, ¹⁰Rheumatology/Immunology, Medical Clinic II, University Clinic Wuerzburg, Würzburg, Germany, ¹¹Rheumatologische Schwerpunktpraxis Erlangen, Erlangen, Germany, ¹²Schwerpunktpraxis Rheumatologie, Erlangen, Germany, ¹³Rheumatologie/Klinische Immunologie, Kreiskliniken Altötting-Burghausen, Burghausen, Germany, ¹⁴Department of Internal Medicine I, University of Regensburg, 93042 Regensburg, Germany, ¹⁵Rheumatology Practice Bamberg, Bamberg, Germany, ¹⁶Internistisch-rheumatologische Praxisgemeinschaft Bayreuth, Bayreuth, Germany, ¹⁷Rheumatology Practice, Bayreuth, Germany, Bayreuth, Germany, ¹⁸Im Neuenheimer Feld 41, UNI-Klinikum Heidelberg, Medizinische Klinik,, Heidelberg, Germany, ¹⁹University of Erlangen, Nürnberg, Germany, ²⁰Rheumazentrum Ruhrgebiet, Herne, Germany, ²¹Department of Internal Medicine II, Division of Rheumatology, University Hospital Tuebingen, Tuebingen, Germany, ²²Praxiszentrum St. Bonifatius, München, Germany
Effects of DMARD Tapering on Treatment Costs and Work Productivity in Rheumatoid Arthritis Patients- an Analysis from the Prospective Randomized Controlled RETRO- Study Background/Purpose: Achieving remission…
Abstract Number: 2118 • 2016 ACR/ARHP Annual Meeting
Rituximab Treated Non Responder Rheumatoid Arthritis Patients Are Generating a New Autoantibody Repertoire
Zoltan Konthur¹, Melvin Michael Wiemkes², Thomas Häupl³, Gerd R. Burmester⁴ and Karl Skriner⁵, ¹Department of Vertebrate Genomics, Max Planck Institute for Molecular Genetics, Berlin, Germany, ²Department of Rheumatology and Clinical Immunology, Germany, Charité - Universitätsmedizin Berlin, Berlin, Germany, ³Department of Rheumatology and Clinical Immunology, Charité University Medicine, Berlin, Germany, ⁴Charité – University Medicine Berlin, Berlin, Germany, ⁵Humboldt University of Berlin, Berlin, Germany
Background/Purpose: Rituximab (RTX) has shown clinical efficacy but up to 40 % of RTX treated rheumatoid arthritis (RA) patients are poor responders (Ann Rheum Dis.…
Abstract Number: 1520 • 2015 ACR/ARHP Annual Meeting
Safety, Clinical and Immunologic Effectiveness of the Live Zoster Vaccine Administered to Patients Receiving Anti-TNF Biologics
Jeffrey R. Curtis^1,2, Anita Turner³, Corretta Thomas⁴, Stacey Cofield⁴, Randall Parks⁵, Jennifer H. Ku⁶, Ilhem Messaoudi- Powers⁷, Keith Wanzeck¹ and Kevin L. Winthrop⁸, ¹University of Alabama at Birmingham, Birmingham, AL, ²Rheumatology & Immunology, University of Alabama-Birmingham, Birmingham, AL, ³Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴School of Public Health, University of Alabama at Birmingham, Birmingham, AL, ⁵Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁶Casey Eye Institute, Oregon Health & Science Univ, Portland, OR, ⁷Oregon Health and Sciences University, Portland, OR, ⁸Oregon Health & Science University, Portland, OR
Background/Purpose: The live herpes zoster vaccine (ZV) has been shown to be safe and effective in large randomized controlled trials of older adults. It is…

« Previous Page
1
…
6
7
8
9
10
…
14
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].